| Literature DB >> 28704971 |
Jie Lin1, Shubin Niu2, Zhengfeng Ding3, Renlei Wang4, Qun Dai5, Wei Wei6, Rongrong Luo7, Ling Liu8.
Abstract
Inflatin G (1), a new aphidicolin analogue, together with seven known compounds inflatin A (2), inflatin B (3), aphidicolin (4), aphidicolin-17-monoacetate (5), gulypyrone A (6), pyridoxatin rotamers A (7) and B (8), were isolated from the ascomycete fungus Tolypocladium inflatum. Their structures were determined through NMR analyses and the circular dichroism data of the in situ formed [Rh₂(OCOCF₃)₄] complexes. Compounds 1, 4, 5, 7, and 8 showed modest cytotoxicity against four human cancer cell lines A549, CNE1-MP1, A375, and MCF-7.Entities:
Keywords: Tolypocladium inflatum; biological activities; structure elucidation
Mesh:
Substances:
Year: 2017 PMID: 28704971 PMCID: PMC6152040 DOI: 10.3390/molecules22071168
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of compounds 1–8.
NMR Data for 1 in Acetone-d6.
| Pos. | HMBC | ||
|---|---|---|---|
| 1a | 27.9, CH2 | 2.20, td (11.0, 3.0) | 9, 20 |
| 1b | 0.96, dt (11.0, 2.5) | 3, 5 | |
| 2a | 27.8, CH2 | 1.67–1.72 | 4, 10 |
| 2b | 1.30–1.36 | ||
| 3 | 81.8, CH | 3.66, t (3.0) | 1, 5, 18, 19, 1′ |
| 4 | 35.7, qC | ||
| 5 | 34.6, CH | 2.82, dd (10.5, 2.5) | 1, 7, 9, 19, 20 |
| 6a | 23.2, CH2 | 1.63, m | 8 |
| 6b | 1.28–1.36 | ||
| 7a | 25.2, CH2 | 1.92–2.02 | 9 |
| 7b | 1.68–1.70 | 5, 9 | |
| 8 | 41.1, CH | 1.96–2.08 | 6, 10, 12 |
| 9 | 49.9, qC | ||
| 10 | 40.6, qC | ||
| 11a | 33.4, CH2 | 1.89–1.91 | 8, 10, 13, 14, 16 |
| 11b | 1.25–1.37 | 10, 14, 16 | |
| 12 | 42.3, CH | 2.13, t (5.7) | 8, 9, 15, 17 |
| 13a | 31.9, CH2 | 1.70–1.72 | 9, 16 |
| 13b | 0.99, dd (11.5, 7.0) | 11, 16 | |
| 14a | 25.5, CH2 | 1.97–2.12 | 8, 10, 11, 16 |
| 14b | 1.71–1.76 | 8, 10, 16 | |
| 15a | 29.3, CH2 | 1.48, dt (12.0, 2.7) | 17 |
| 15b | 1.30, td (12.0, 5.0) | 9, 12 | |
| 16 | 74.3, qC | ||
| 17a | 68.3, CH2 | 3.37, dd (9.0, 5.0) | 12, 15 |
| 17b | 3.27, dd (9.0, 5.0) | 12, 15 | |
| 18a | 76.2, CH2 | 4.02, d (10.0) | 3, 1′ |
| 18b | 3.16, d (10.0) | 3, 5, 19, 1′ | |
| 19 | 17.2, CH3 | 0.76, s | 3, 5, 18 |
| 20 | 16.0, CH3 | 1.05, s | 1, 5, 9 |
| 1′ | 102.4, CH | 5.51, s | 3, 18, 3′, 7′ |
| 2′ | 140.6, qC | ||
| 3′ | 127.3, CH | 7.51, d (6.5) | 1′, 5′, 7′ |
| 4′ | 128.8, CH | 7.35, d (6.5) | 2′, 6′ |
| 5′ | 129.3, CH | 7.36, m | |
| 6′ | 128.8, CH | 7.35, d (6.5) | 2′, 4′ |
| 7′ | 127.3, CH | 7.51, d (6.5) | 1′, 3′, 5′ |
| OH-16 | 3.07, s | ||
| OH-17 | 3.50, t (5.0) |
Recorded at 125 MHz; Recorded at 500 MHz; Signals overlapping.
Figure 2Key 1H-1H COSY, HMBC and NOESY correlations for 1.
Figure 3Thermal ellipsoid representation of 4.
Figure 4CD spectrum of Rh-complex of 1 with the inherent CD spectrum subtracted.
Cytotoxicity of Compounds 1, 4–8 Against Human Tumor Cell Lines.
| Compound | IC50 (µM) | ||||
|---|---|---|---|---|---|
| A549 | CNE1-LMP1 | A375 | MCF-7 | HaCaT | |
| 68.7 | 35.4 | 39.8 | 35.2 | 42.6 | |
| 16.2 | 3.12 | 37.3 | 42.3 | 10.4 | |
| 5.20 | 4.00 | 40.5 | 66.2 | 8.00 | |
| >100 | >100 | >100 | >100 | >100 | |
| 0.44 | 0.20 | 0.10 | 0.17 | >47.5 | |
| paclitaxel | 3.0 × 10−2 | 4.2 × 10−3 | 8.9 × 10−3 | 1.4 × 10−2 | 0.024 |
Lung adenocarcinoma cells; Stable oncoprotein LMP1 integrated nasopharyngeal carcinoma cells; Malignant melanoma cells; Breast cancer cells; Keratinocyte cells.